Managing imipenem-resistant Acinetobacter baumannii in a hospital setting
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital: A Retrospective Study
This study looks at how to manage outbreaks of a tough-to-treat bacteria called Acinetobacter baumannii in a hospital to help improve care for affected patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 148 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06173440 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the management of imipenem-resistant Acinetobacter baumannii (IBA) outbreaks in a surgical resuscitation department at a French university hospital. It aims to analyze the colonization and infection patterns of patients affected during a specific epidemic period from May 2015 to January 2019. The study seeks to provide a detailed account of the challenges and strategies involved in controlling such outbreaks, which are critical due to the bacterium's resistance and the severe infections it can cause. By examining patient data, the study hopes to contribute valuable insights into effective management practices for similar future incidents.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who were hospitalized in the surgical resuscitation service during the specified outbreak period and were colonized or infected by IBA.
Not a fit: Patients who were not hospitalized during the outbreak or who did not have any colonization or infection with IBA will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance infection control measures and improve patient outcomes in cases of imipenem-resistant Acinetobacter baumannii infections.
How similar studies have performed: While there is limited literature on managing IBA outbreaks, similar studies have shown that effective infection control measures can significantly reduce the impact of resistant bacterial infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Major subject (≥18 years old) * Patient having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI (according to bacteriological results transmitted to the hygiene service). * Subject having given his/her agreement, after information, for the reuse of his/her data for the purpose of this research Exclusion criteria: * Subject having expressed his opposition to participate in the study * Subject under guardianship or curatorship * Subject under legal protection
Where this trial is running
Strasbourg
- Service Equipe opérationnelle d'hygiène - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Stéphanie DEBOSCKER, MD
- Email: stephanie.deboscker@chru-strasbourg.fr
- Phone: 33 3 69 55 03 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.